Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) Net Margin (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Net Margin for 6 consecutive years, with 5.44% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Margin rose 810140.0% year-over-year to 5.44%, compared with a TTM value of 549.62% through Sep 2025, up 608325.0%, and an annual FY2024 reading of 4670.14%, up 868164.0% over the prior year.
  • Net Margin was 5.44% for Q3 2025 at Ovid Therapeutics, up from 74.68% in the prior quarter.
  • Across five years, Net Margin topped out at 5042.01% in Q2 2024 and bottomed at 107798.32% in Q3 2022.
  • Average Net Margin over 5 years is 11662.77%, with a median of 932.23% recorded in 2025.
  • Peak annual rise in Net Margin hit 9747447bps in 2023, while the deepest fall reached -1844658bps in 2023.
  • Year by year, Net Margin stood at 84.46% in 2021, then tumbled by -106bps to 5.17% in 2022, then tumbled by -199561bps to 10323.85% in 2023, then fell by -18bps to 12175.0% in 2024, then skyrocketed by 100bps to 5.44% in 2025.
  • Business Quant data shows Net Margin for OVID at 5.44% in Q3 2025, 74.68% in Q2 2025, and 4.58% in Q1 2025.